Aldeyra Therapeutics (ALDX) Change in Accured Expenses (2013 - 2026)

Aldeyra Therapeutics (ALDX) has 14 years of Change in Accured Expenses data on file, last reported at -$1.2 million in Q1 2026.

• Quarterly Change in Accured Expenses rose 75.99% year-over-year to -$1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.4 million (down 268.34% YoY) and the FY2025 annual result came in at -$6.3 million, down 226.59% from the prior year.
• Change in Accured Expenses retreated to -$1.2 million in Q1 2026, from -$564859.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $3.0 million in Q3 2024 to a low of -$5.2 million in Q1 2025.
• A 5-year average of -$555701.7 and a median of -$564859.0 in 2025 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses surged 4373.66% — and 2025, when it plunged 1148.53%.
• Tracing ALDX's Change in Accured Expenses over 5 years: stood at $2.5 million in 2022, then sank by 102.52% to -$62147.0 in 2023, then soared by 3023.13% to $1.8 million in 2024, then plunged by 131.09% to -$564859.0 in 2025, then slumped by 119.61% to -$1.2 million in 2026.
• The last three Change in Accured Expenses figures came in at -$1.2 million (Q1 2026), -$564859.0 (Q4 2025), and -$795365.0 (Q3 2025), per Business Quant data.